RPS6KB1 and lymphangioleiomyomatosis: We used pS6 (Ser235/236) as the surrogate for activation of S6K protein synthetic pathways, since the immunoblot signal for pS6K in these LAM cell lines and in some of our TSC2-null cells was weak.